Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment

被引：0

作者：

Poplin, Elizabeth

Wasan, Harpreet

Rolfe, Lindsey

Raponi, Mitch

Ikdahl, Tone

Bondarenko, Ihor

Davidenko, Irina

Bondar, Volodymyr

Garin, August

Boeck, Stefan Hubert

Heinemann, Volker

Bassi, Claudio

Evans, T. R. Jeffry

Voong, Cynthia

Kaur, Paramjit

Isaacson, Jeffrey D.

Allen, Andrew R.

机构：

[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA

[2] Imperial Coll Healthcare NHS Trust, London, England

[3] Clovis Oncol Inc, Boulder, CO USA

[4] Clovis Oncol Inc, San Francisco, CA USA

[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[6] Dnipropetrovsk State Med Acad, Dnepropetrovsk, Ukraine

[7] Krasnodar City Oncol Ctr, Krasnodar, Russia

[8] Donetsk Reg Antitumor Ctr, Donetsk, Ukraine

[9] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia

[10] Ludwig Maximilians Univ Munchen, Dept Hematol & Oncol, Klinikum Grosshadern, Munich, Germany

[11] Ludwig Maximilians Univ Munchen, Ctr Comprehens Canc, Munich, Germany

[12] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany

[13] Univ Verona, Dept Surg, I-37100 Verona, Italy

[14] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4007

引用

页数：2

共 50 条

[1] Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Poplin, Elizabeth
Wasan, Harpreet
Rolfe, Lindsey
Raponi, Mitch
Ikdahl, Tone
Bondarenko, Ihor
Davidenko, Irina
Bondar, Volodymyr
Garin, August
Boeck, Stefan
Ormanns, Steffen
Heinemann, Volker
Bassi, Claudio
Evans, T. R. Jeffrey
Andersson, Roland
Hahn, Hejin
Picozzi, Vince
Dicker, Adam
Mann, Elaina
Voong, Cynthia
Kaur, Paramjit
Isaacson, Jeff
Allen, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4453 - 4461
[2] A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy.
Ikdahl, T.
Davidenko, I.
Bassi, C.
Tomasetto, E.
Smith, L.
McLachlan, S.
Jones, S.
Raponi, M.
Isaacson, J.
Voong, C.
Rolfe, L.
Allen, A. R.
Poplin, E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] High hENT1 Expression is Predictive of Response of to Adjuvant Gemcitabine for Pancreatic Ductal Adenocarcinoma Patients Randomized to Adjuvant Therapies in the ESPAC Trials
Neoptolemos, J. P.
Cox, T. F.
Greenhalf, W.
Garner, L.
Campbell, F.
Ghaneh, P.
Palmer, D.
Mackey, J.
Dervenis, C.
Scarpa, A.
Bassi, C.
Buechler, M. W.
PANCREAS, 2012, 41 (08) : 1390 - 1390
[4] A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Li, D.
Pant, S.
Ryan, D. P.
Laheru, D.
Bahary, N.
Dragovich, T.
Hosein, P. J.
Rolfe, L.
Saif, M. W.
LaValle, J.
Yu, K. H.
Lowery, M. A.
Allen, A.
O'Reilly, E. M.
PANCREATOLOGY, 2014, 14 (05) : 398 - 402
[5] HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Hingorani, Sunil R.
Zheng, Lei
Bullock, Andrea J.
Seery, Tara E.
Harris, William P.
Sigal, Darren S.
Braiteh, Fadi
Ritch, Paul S.
Zalupski, Mark M.
Bahary, Nathan
Oberstein, Paul E.
Wang-Gillam, Andrea
Wu, Wilson
Chondros, Dimitrios
Jiang, Ping
Khelifa, Sihem
Pu, Jie
Aldrich, Carrie
Hendifar, Andrew E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 359 - +
[6] Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat, Eric
Mineur, Laurent
Mollevi, Caroline
Lombard-Bohas, Catherine
Mazard, Thibault
Samalin, Emmanuelle
Portales, Fabienne
Walter, Thomas
Ychou, Marc
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[7] Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study.
Viret, F
Ychou, M
Lepille, D
Mineur, L
Navarro, F
Topart, D
Fonck, M
Goineau, J
Madroszyk-Flandin, A
Chouaki, N
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 342S - 342S
[8] Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.
Chua, Yu Jo
Karapetis, Christos Stelios
Gebski, Val
O'Connell, Rachel
Begbie, Stephen
Nott, Louise M.
Cronk, Michelle F.
Underhill, Craig
Abdi, Ehtesham A.
Van Hagen, Thomas
Wong, Nicole
Hall, Merryn
Ferraro, Danielle Angela
Sjoquist, Katrin Marie
Santos, Cheryl
Mackey, John Robert
Goldstein, David
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[9] A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma
Bai, Li-Yuan
Li, Chung-Pin
Shan, Yan-Shen
Chuang, Shih-Chang
Chen, Jen-Shi
Chiang, Nai-Jung
Chen, Yen-Yang
Tsou, Hsiao-Hui
Chuang, Mei-Hsing
Chiu, Chang-Fang
Liu, Tsang-Wu
Chen, Li-Tzong
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
Alberts, SR
Foster, NR
Morton, RF
Kugler, J
Schaefer, P
Wiesenfeld, M
Fitch, TR
Steen, P
Kim, GP
Gill, S
ANNALS OF ONCOLOGY, 2005, 16 (10) : 1654 - 1661

← 1 2 3 4 5 →